Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Trial Profile

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NYX-783 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Sponsors Aptinyx
  • Most Recent Events

    • 23 Jun 2020 Planned End Date changed from 30 May 2020 to 30 Dec 2020.
    • 23 Jun 2020 Planned primary completion date changed from 30 May 2020 to 30 Dec 2020.
    • 18 Jun 2020 Accordding to an Aptinyx media release, data from this study is anticipated in late 2020. The company looks forward to complete the study in coming months.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top